- Home
- NVRI vs TYRA Comparison
NVRI vs TYRA Comparison
Compare NVRI & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRI
- TYRA
- Stock Information
- Founded
- NVRI 1853
- TYRA 2018
- Country
- NVRI United States
- TYRA United States
- Employees
- NVRI N/A
- TYRA 60
- Industry
- NVRI Diversified Commercial Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- NVRI Miscellaneous
- TYRA Health Care
- Exchange
- NVRI Nasdaq
- TYRA Nasdaq
- Market Cap
- NVRI 521.3M
- TYRA 556.4M
- IPO Year
- NVRI N/A
- TYRA 2021
- Fundamental
- Price
- NVRI $7.11
- TYRA $10.07
- Analyst Decision
- NVRI Hold
- TYRA Strong Buy
- Analyst Count
- NVRI 1
- TYRA 6
- Target Price
- NVRI $10.00
- TYRA $30.50
- AVG Volume (30 Days)
- NVRI 697.5K
- TYRA 287.0K
- Earning Date
- NVRI 05-01-2025
- TYRA 05-16-2025
- Dividend Yield
- NVRI N/A
- TYRA N/A
- EPS Growth
- NVRI N/A
- TYRA N/A
- EPS
- NVRI N/A
- TYRA N/A
- Revenue
- NVRI $2,290,612,000.00
- TYRA N/A
- Revenue This Year
- NVRI N/A
- TYRA N/A
- Revenue Next Year
- NVRI $3.63
- TYRA N/A
- P/E Ratio
- NVRI N/A
- TYRA N/A
- Revenue Growth
- NVRI N/A
- TYRA N/A
- 52 Week Low
- NVRI $4.72
- TYRA $6.42
- 52 Week High
- NVRI $12.79
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- NVRI 62.50
- TYRA 52.78
- Support Level
- NVRI $6.67
- TYRA $8.80
- Resistance Level
- NVRI $7.42
- TYRA $10.56
- Average True Range (ATR)
- NVRI 0.34
- TYRA 0.78
- MACD
- NVRI 0.11
- TYRA 0.07
- Stochastic Oscillator
- NVRI 81.58
- TYRA 71.16
About NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.